Table 26CADTH Revisions to the Submitted Budget Impact Analysis

Stepped analysis Sponsor’s value or assumption CADTH value or assumption
Corrections to sponsor’s base case
None.——
Changes to derive the CADTH base case
1. NIHB Population (base year)Total Population: 30,564,619

NIHB Population: 887,518

Ontario Population: 14,915,270

Total Population: 29,826,786

NIHB Population: 805,330

Ontario Population: 14,794,293

2. Uptake of edaravone in new drug scenario (Y1 / Y2 / Y3)12% / 14% / 15%15% / 20% / 25%
3. Proportion edaravone patients using the oral formulation (Y1 / Y2 / Y3)Edaravone experienced: 72.2% / 78.6% / 79.4%

Edaravone naive: 72.2% / 78.6% / 79.4%

Edaravone experienced: 80% / 95% / 95%

Edaravone naive: 100% / 100% / 100%

CADTH base case1 + 2 + 3

NIHB = Noninsured Health Benefits; Y = year.

From: Edaravone Oral Suspension (Radicava)

Cover of Edaravone Oral Suspension (Radicava)
Edaravone Oral Suspension (Radicava): CADTH Reimbursement Review: Therapeutic area: Amyotrophic lateral sclerosis [Internet].
Copyright Notice

Copyright © 2023 - Canadian Agency for Drugs and Technologies in Health. Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial- NoDerivatives 4.0 International licence (CC BY-NC-ND).

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.